STUDIES SHOW: Safe at therapeutic doses ( 57 mg/kg) Early studies suggest cognitive and neurological benefits, such as memory enhancement, reduced delirium in surgery, and potential support in neurodegenerative and psychiatric contexts
Importantly, with a myosin inhibitor lowers HO, lessens arrhythmias, and protects CK function, pointing to workload reduction as a direct way to restore energetic balance
The baseline panel Here is the complete list of tests to request before starting tirzepatide: Metabolic markers: Comprehensive metabolic panel (CMP), which includes glucose, electrolytes, BUN, creatinine, calcium, and liver enzymes Hemoglobin A1c (HbA1c), your 2-3 month blood sugar average Fasting insulin and fasting glucose HOMA-IR calculation (derived from fasting insulin and glucose) Lipid panel: Total cholesterol LDL cholesterol (direct measurement preferred) HDL cholesterol Triglycerides VLDL cholesterol Liver function: ALT (alanine aminotransferase) AST (aspartate aminotransferase) Alkaline phosphatase (ALP) Total bilirubin GGT (gamma-glutamyl transferase), optional but useful Kidney function: Serum creatinine Blood urea nitrogen (BUN) Estimated glomerular filtration rate (eGFR) Cystatin C (recommended for more accurate kidney assessment) Urine albumin-to-creatinine ratio (UACR), especially if diabetic Thyroid function: TSH (thyroid stimulating hormone) Free T4 Free T3 (optional but informative) Thyroid antibodies if history of thyroid disease Complete blood count (CBC): White blood cells, red blood cells, hemoglobin, hematocrit, platelets Differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) Additional recommended tests: Vitamin B12 (especially if taking tirzepatide with B12 ) Vitamin D Iron panel (ferritin, TIBC, serum iron) Magnesium Pancreatic enzymes (lipase, amylase), baseline reference This might seem like an extensive list
10.1074/jbc.M305838200 151 ShoupD.PriolaS
Understanding the general peptide safety landscape helps put these results in context
So I wrote a little thing for @MolMetab sciencedirect.com/science/articl As we now appreciate, GLP-1 can target multiple brain regions and neuronal populations to reduce food intake, and the clinical results are increasingly impressive #obesity The ongoing SELECT trial will be pivotal for the field sciencedirect.com/science/articl From very modest weight loss with exenatide twice daily, the GLP-1 field has learned, by titration, dose escalation, higher Cmax, and better molecules, to achieve clinically meaningful #weightloss #T2D #obesity More progress to come #obesity described here sciencedirect.com/science/articl Beyond semaglutide and tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and make projections out to 52 weeks thelancet.com/journals/lance Join the conversation
